Celldex Completes Enrollment in Phase 2 Study of Barzolvolimab in CIndU
Patient enrollment is now complete in Celldex’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). Mast cell activation is known to be a critical driver in ColdU and SD, and barzolvolimab is a humanized monoclonal antibody that […]